OPHLY
Ono Pharmaceutical Co Ltd
A research-driven Japanese drugmaker based in Osaka that develops medicines for cancer, immunology, and neurology. Its flagship product is Opdivo, an immune-checkpoint cancer treatment co-developed with Bristol Myers Squibb. The company traces its roots to 1717, when Ichibei Ono I opened an apothecary called Fushimiya Ichibei in Osaka's Doshomachi district — the same family name that still heads the firm today.
ADRUnderlying: OPHLYCINS: J61546115HealthcareJP1 holder
Unsponsored ADR (3:1 ratio, underlying Tokyo: 4528)
Total Value
$531.8K
Total Shares
29.8K
Net Share Change
-4.5K
Activity
1 selling
Investor
Value
Shares
Weight
Change
